Andere talen Werewolf Therapeutics, Inc.

Aandelen

HOWL

US95075A1079

Geschatte realtime Cboe BZX Andere beurzen 16:20:39 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,28 ^USD	+0,64%		-2,00%	+62,24%

23/04	Werewolf Therapeutics, Inc. presenteert eerste preklinische gegevens die IL-10 INDUKINE moleculen benadrukken als potentiële therapie voor inflammatoire darmziekten op de jaarlijkse AAI-bijeenkomst	CI
05/04	Werewolf Therapeutics, Inc. presenteert preklinische resultaten die anti-tumor effecten aantonen van pro-inflammatoire cytokine therapeutica	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	23/04
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	23/04
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	05/04
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	05/04
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	04/04
Werewolf Therapeutics' Q4 Net Loss Narrows	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	06/03
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	05/03
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	08/01
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	04/01
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	04/01
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	22/11
North American Morning Briefing : Stocks Seen -2-	15/11
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	14/11
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Stronger Late Afternoon	03/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Werewolf Therapeutics, Inc.

Aandelen

HOWL

US95075A1079

Andere talen

Filters